NO318379B1 - Ester av 5-aminolevulinsyre som fotosensibiliseringsmiddel i fotokjemoterapi, anvendelse derav, samt farmasoytisk blanding, produkt, utstyrsett og fremgangsmate for in vitro-diagnostisering. - Google Patents
Ester av 5-aminolevulinsyre som fotosensibiliseringsmiddel i fotokjemoterapi, anvendelse derav, samt farmasoytisk blanding, produkt, utstyrsett og fremgangsmate for in vitro-diagnostisering. Download PDFInfo
- Publication number
- NO318379B1 NO318379B1 NO19974163A NO974163A NO318379B1 NO 318379 B1 NO318379 B1 NO 318379B1 NO 19974163 A NO19974163 A NO 19974163A NO 974163 A NO974163 A NO 974163A NO 318379 B1 NO318379 B1 NO 318379B1
- Authority
- NO
- Norway
- Prior art keywords
- ala
- fluorescence
- photochemotherapy
- ester
- skin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 21
- 238000003745 diagnosis Methods 0.000 title claims description 14
- 238000000338 in vitro Methods 0.000 title claims description 5
- 229960002749 aminolevulinic acid Drugs 0.000 title description 149
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 title description 100
- 150000002148 esters Chemical class 0.000 title description 23
- 239000003504 photosensitizing agent Substances 0.000 title description 14
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 hexyl ester Chemical class 0.000 claims description 65
- 150000001875 compounds Chemical class 0.000 claims description 41
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 34
- 230000005856 abnormality Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 150000003839 salts Chemical group 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000002738 chelating agent Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 230000003211 malignant effect Effects 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 150000004702 methyl esters Chemical class 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 150000002390 heteroarenes Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004437 phosphorous atom Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 208000035874 Excoriation Diseases 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 49
- 210000003491 skin Anatomy 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 39
- 150000004032 porphyrins Chemical class 0.000 description 36
- 206010028980 Neoplasm Diseases 0.000 description 34
- 230000037311 normal skin Effects 0.000 description 33
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 30
- 230000000699 topical effect Effects 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 25
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 24
- 229960000958 deferoxamine Drugs 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 238000005259 measurement Methods 0.000 description 21
- 230000003902 lesion Effects 0.000 description 19
- 238000011200 topical administration Methods 0.000 description 19
- 238000001574 biopsy Methods 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000006071 cream Substances 0.000 description 16
- 230000002215 photochemotherapeutic effect Effects 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 13
- 238000000386 microscopy Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000005886 esterification reaction Methods 0.000 description 10
- 150000003278 haem Chemical class 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000002165 photosensitisation Effects 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- 229950010481 5-aminolevulinic acid hydrochloride Drugs 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000032050 esterification Effects 0.000 description 6
- 238000000799 fluorescence microscopy Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241000024188 Andala Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 4
- 102000003875 Ferrochelatase Human genes 0.000 description 4
- 108010057394 Ferrochelatase Proteins 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000013307 optical fiber Substances 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 229950003776 protoporphyrin Drugs 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000037368 penetrate the skin Effects 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- LZYXPFZBAZTOCH-UHFFFAOYSA-N hexyl 5-amino-4-oxopentanoate;hydron;chloride Chemical compound Cl.CCCCCCOC(=O)CCC(=O)CN LZYXPFZBAZTOCH-UHFFFAOYSA-N 0.000 description 2
- 239000008309 hydrophilic cream Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- UJYSYPVQHFNBML-UHFFFAOYSA-N methyl 5-aminolevulinate hydrochloride Chemical compound [Cl-].COC(=O)CCC(=O)C[NH3+] UJYSYPVQHFNBML-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 201000000743 nodular basal cell carcinoma Diseases 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229940109328 photofrin Drugs 0.000 description 2
- 230000036211 photosensitivity Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229910052705 radium Inorganic materials 0.000 description 2
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- VDPRSOCKHVPZRS-UHFFFAOYSA-N 1-(2-decylsulfanylethyl)pyrrolidin-2-one Chemical compound CCCCCCCCCCSCCN1CCCC1=O VDPRSOCKHVPZRS-UHFFFAOYSA-N 0.000 description 1
- ILBBNQMSDGAAPF-UHFFFAOYSA-N 1-(6-hydroxy-6-methylcyclohexa-2,4-dien-1-yl)propan-1-one Chemical compound CCC(=O)C1C=CC=CC1(C)O ILBBNQMSDGAAPF-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- RNMCCPMYXUKHAZ-UHFFFAOYSA-N 2-[3,3-diamino-1,2,2-tris(carboxymethyl)cyclohexyl]acetic acid Chemical compound NC1(N)CCCC(CC(O)=O)(CC(O)=O)C1(CC(O)=O)CC(O)=O RNMCCPMYXUKHAZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZLHFONARZHCSET-UHFFFAOYSA-N 5-aminolevulinic acid hydrochloride Chemical compound Cl.NCC(=O)CCC(O)=O ZLHFONARZHCSET-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- QSHWIQZFGQKFMA-UHFFFAOYSA-N Porphobilinogen Natural products NCC=1NC=C(CCC(O)=O)C=1CC(O)=O QSHWIQZFGQKFMA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000004035 chlorins Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- MGTYUHPAVHGVQF-UHFFFAOYSA-N ethyl 5-amino-4-oxopentanoate;hydrochloride Chemical compound Cl.CCOC(=O)CCC(=O)CN MGTYUHPAVHGVQF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- FLWXZETXCKMYJP-UHFFFAOYSA-N heptyl 5-amino-4-oxopentanoate;hydrochloride Chemical compound Cl.CCCCCCCOC(=O)CCC(=O)CN FLWXZETXCKMYJP-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000012625 in-situ measurement Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- GXGLFZOHIPQGLL-UHFFFAOYSA-N octyl 5-amino-4-oxopentanoate;hydrochloride Chemical compound Cl.CCCCCCCCOC(=O)CCC(=O)CN GXGLFZOHIPQGLL-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- YPHQRHBJEUDWJW-UHFFFAOYSA-N porphobilinogen Chemical compound NCC1=NC=C(CCC(O)=O)[C]1CC(O)=O YPHQRHBJEUDWJW-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- JMCJOMAISPJJIH-UHFFFAOYSA-N propyl 5-amino-4-oxopentanoate;hydrochloride Chemical compound Cl.CCCOC(=O)CCC(=O)CN JMCJOMAISPJJIH-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9504948.2A GB9504948D0 (en) | 1995-03-10 | 1995-03-10 | Compounds |
| GBGB9525822.4A GB9525822D0 (en) | 1995-12-18 | 1995-12-18 | Compounds |
| PCT/GB1996/000553 WO1996028412A1 (en) | 1995-03-10 | 1996-03-08 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO974163D0 NO974163D0 (no) | 1997-09-09 |
| NO974163L NO974163L (no) | 1997-09-09 |
| NO318379B1 true NO318379B1 (no) | 2005-03-14 |
Family
ID=26306657
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19974163A NO318379B1 (no) | 1995-03-10 | 1997-09-09 | Ester av 5-aminolevulinsyre som fotosensibiliseringsmiddel i fotokjemoterapi, anvendelse derav, samt farmasoytisk blanding, produkt, utstyrsett og fremgangsmate for in vitro-diagnostisering. |
| NO2005019C NO2005019I2 (no) | 1995-03-10 | 2005-09-13 | Metylaminolevulinat, eventuelt i form av et salt, fortrinnsvis metylaminolevulinat-hydroklorid |
| NO2005024C NO2005024I2 (no) | 1995-03-10 | 2005-11-07 | Ester av 5-aminolevulinsyre som fotosensibiliseringsmiddel i fotokjemoterapi, anvendelse derav, samtfarmasoytisk blanding, produkt, utstyrsett og fre mgangsmaate for in vitro-diagnostisering |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2005019C NO2005019I2 (no) | 1995-03-10 | 2005-09-13 | Metylaminolevulinat, eventuelt i form av et salt, fortrinnsvis metylaminolevulinat-hydroklorid |
| NO2005024C NO2005024I2 (no) | 1995-03-10 | 2005-11-07 | Ester av 5-aminolevulinsyre som fotosensibiliseringsmiddel i fotokjemoterapi, anvendelse derav, samtfarmasoytisk blanding, produkt, utstyrsett og fre mgangsmaate for in vitro-diagnostisering |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6034267A (xx) |
| EP (1) | EP0820432B1 (xx) |
| JP (1) | JP3955093B2 (xx) |
| KR (1) | KR100444007B1 (xx) |
| CN (1) | CN1137087C (xx) |
| AT (1) | ATE202076T1 (xx) |
| AU (1) | AU708076B2 (xx) |
| CA (1) | CA2215069C (xx) |
| CZ (1) | CZ291132B6 (xx) |
| DE (3) | DE122006000051I1 (xx) |
| ES (1) | ES2157424T3 (xx) |
| FR (1) | FR05C0042I2 (xx) |
| HU (1) | HU225148B1 (xx) |
| LU (1) | LU90956I2 (xx) |
| NL (2) | NL300176I2 (xx) |
| NO (3) | NO318379B1 (xx) |
| NZ (1) | NZ303251A (xx) |
| PT (1) | PT820432E (xx) |
| WO (1) | WO1996028412A1 (xx) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7530461B2 (en) * | 1995-03-10 | 2009-05-12 | Photocure Asa | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| US6992107B1 (en) | 1995-03-10 | 2006-01-31 | Photocure Asa | Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy |
| US6492420B2 (en) * | 1995-03-10 | 2002-12-10 | Photocure As | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| US5895786A (en) * | 1996-05-08 | 1999-04-20 | New York Blood Center, Inc. | Method for treating viral infections |
| GB9700396D0 (en) | 1997-01-10 | 1997-02-26 | Photocure As | Photochemotherapeutic compositions |
| FR2777782B1 (fr) * | 1998-04-22 | 2001-05-18 | Alexandre Marti | Solution pour la preparation d'une substance pharmaceutique pour le diagnostic et/ou le traitement de lesions tissulaires |
| US6223071B1 (en) | 1998-05-01 | 2001-04-24 | Dusa Pharmaceuticals Inc. | Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light |
| DE19852245A1 (de) * | 1998-11-12 | 2000-05-18 | Asat Ag Applied Science & Tech | 5-Aminolävulinsäure-Nanoemulsion |
| AU782726B2 (en) | 1999-07-28 | 2005-08-25 | Commissariat A L'energie Atomique | Integration of biochemical protocols in a continuous flow microfluidic device |
| JP3970492B2 (ja) * | 1999-12-14 | 2007-09-05 | コスモ石油株式会社 | ピーリング用組成物 |
| DE10003620A1 (de) * | 2000-01-28 | 2001-08-02 | Asat Ag Applied Science & Tech | 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln |
| NO20002428D0 (no) | 2000-05-10 | 2000-05-10 | Radiumhospitalets Forskningsst | Hudpreparat |
| US6454790B1 (en) * | 2000-07-21 | 2002-09-24 | Ceramoptec Industries, Inc. | Treatment for Barrett's syndrome |
| GB0018527D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Composition |
| GB0018528D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| EP1318807A4 (en) * | 2000-08-11 | 2008-02-20 | Ceramoptec Gmbh | LIGHT-SENSITIVE OINTMENT |
| ATE319079T1 (de) * | 2000-11-06 | 2006-03-15 | Alfons Prof Dr Med Hofstetter | Tumorzellenidentifizierungsverfahren |
| AU2002220853B2 (en) | 2000-11-29 | 2007-06-28 | Pci Biotech As | Photochemical internalization for delivery of molecules into the cytosol |
| AU2002222104B2 (en) | 2000-11-29 | 2007-06-28 | Pci Biotech As | Photochemical internalization for virus-mediated molecule delivery into the cyosol |
| EP1312353A1 (en) * | 2001-11-16 | 2003-05-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for hair removal |
| US6723750B2 (en) | 2002-03-15 | 2004-04-20 | Allergan, Inc. | Photodynamic therapy for pre-melanomas |
| WO2003086460A2 (en) * | 2002-04-05 | 2003-10-23 | Candela Corporation | High fluence rate activation of photosensitizers for dermatological applications |
| DE10301917B4 (de) * | 2003-01-17 | 2007-02-01 | Gerhard Saalmann | Verwendung von Substanzen der Porphyrinsynthese bei der Phototherapie von Haut- oder Gelenkerkrankungen des Menschen oder von Säugetieren |
| DE10312659A1 (de) * | 2003-03-21 | 2004-10-07 | Universität Regensburg | 5-Aminolävulinsäurederivate und ihre Verwendung |
| US20050209331A1 (en) * | 2004-03-22 | 2005-09-22 | Syneron Medical Ltd. | Method of treatment of skin |
| GB0406917D0 (en) * | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
| CN1942163B (zh) * | 2004-04-28 | 2010-11-24 | 克斯莫石油公司 | 生发剂 |
| JP2005350418A (ja) * | 2004-06-11 | 2005-12-22 | Shibuya Kogyo Co Ltd | 標的細胞の死滅方法と標的細胞を死滅させるための薬剤及び該薬剤の製造装置 |
| JP5034032B2 (ja) * | 2004-09-29 | 2012-09-26 | Ｓｂｉファーマ株式会社 | 腫瘍診断剤 |
| GB0424833D0 (en) * | 2004-11-10 | 2004-12-15 | Photocure Asa | Method |
| GB0515550D0 (en) | 2005-07-29 | 2005-09-07 | Univ Strathclyde | Inactivation of staphylococcus species |
| US20070225518A1 (en) * | 2006-03-22 | 2007-09-27 | Zvi Malik | 5-Aminolevulinic acid salts and their use |
| KR100796450B1 (ko) * | 2006-06-29 | 2008-01-22 | 전남대학교산학협력단 | 5-아미노레불린산의 불포화 알킬 에스터 및 약학적으로허용되는 그의 염, 이의 제조방법 및 이의 용도 |
| GB0700580D0 (en) * | 2007-01-11 | 2007-02-21 | Photocure Asa | Use |
| JP5098051B2 (ja) | 2007-04-05 | 2012-12-12 | Ｓｂｉファーマ株式会社 | ミトコンドリア障害脳疾患治療剤及び診断剤 |
| AU2014200004B2 (en) * | 2007-12-12 | 2016-10-27 | Photocure Asa | Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis |
| GB0724279D0 (en) * | 2007-12-12 | 2008-01-23 | Photocure Asa | Use |
| CA2709274A1 (en) | 2007-12-14 | 2009-06-25 | Photoderma Sa | Novel compounds useful in therapeutic and cosmetic methods |
| CN102123587B (zh) | 2008-05-13 | 2014-07-30 | 克斯莫石油株式会社 | 草坪草的品质提高剂 |
| CN102014890B (zh) | 2008-05-14 | 2015-08-05 | 思佰益药业股份有限公司 | 男性不育治疗剂 |
| AU2009286182B2 (en) | 2008-09-01 | 2013-11-07 | Swedish Pharma Ab | New 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis |
| CN101745102B (zh) * | 2008-12-16 | 2013-08-07 | 上海复旦张江生物医药股份有限公司 | 5-氨基酮戊酸及其衍生物的组合物及其用途 |
| GB0823472D0 (en) | 2008-12-23 | 2009-01-28 | Photocure Asa | Product |
| GB0900461D0 (en) | 2009-01-12 | 2009-02-11 | Photocure Asa | Photodynamic therapy device |
| US20100256125A1 (en) * | 2009-04-06 | 2010-10-07 | Zila Pharmaceuticals, Inc. | Use of improved toluidine blue in photodynamic therapy |
| BRPI1011316B8 (pt) | 2009-05-26 | 2021-06-22 | Massachusetts Gen Hospital | aparelho para administrar uma substância ao tecido da pele |
| EP3042647B1 (en) | 2009-06-11 | 2020-08-26 | Photocure ASA | Semi-solid compositions and pharmaceutical products comprising 5-aminolevulinic acid esters |
| PE20120858A1 (es) * | 2009-06-11 | 2012-08-01 | Photocure Asa | Composiciones solidas que comprenden acido 5-aminolevulinico |
| KR101133770B1 (ko) * | 2009-10-27 | 2012-04-09 | 주식회사 엔씨테크론 | 메틸 5-아미노레불리네이트 염산염의 제조방법과 이를 이용한 여드름 및 피부 개선을 위한 피부 외용 화장료 조성물 및 이의 제조방법 |
| WO2011107478A1 (en) | 2010-03-01 | 2011-09-09 | Photocure Asa | Cosmetic compositions |
| EP2394642A1 (en) | 2010-06-10 | 2011-12-14 | Universite De Geneve | 5-ALA ester formulations and use thereof |
| WO2011161220A1 (en) | 2010-06-23 | 2011-12-29 | Photocure Asa | Hyperosmotic preparations comprising 5 -amino levulinic acid or derivative as photosensitizing agent |
| WO2012004399A1 (en) | 2010-07-09 | 2012-01-12 | Photocure Asa | Dry compositions and devices containing such dry compositions for use in photodynamic therapy or photodynamic diagnosis |
| US9012502B2 (en) | 2010-09-14 | 2015-04-21 | Sbi Pharmaceuticals Co., Ltd. | Cancer heat therapy-enhancing agent |
| ES2755677T3 (es) * | 2010-09-30 | 2020-04-23 | Cosmo Trade & Service Co Ltd | Fertilizante sólido que contiene ácido 5-aminolevulínico y procedimiento para producir el mismo |
| JP6323978B2 (ja) | 2010-12-24 | 2018-05-16 | アークレイ株式会社 | 癌細胞の検出方法 |
| CN102617378B (zh) * | 2011-01-26 | 2016-04-27 | 上海泺安医药技术有限公司 | 一种2-(3’-氨基-2’-氧-丙基)丙二酸酯盐及制备 |
| CN102649768B (zh) * | 2011-02-25 | 2016-05-25 | 上海泺安医药技术有限公司 | 一种盐酸氨基乙酰丙酸的制备工艺 |
| CN102649769B (zh) * | 2011-02-25 | 2015-12-16 | 上海泺安医药技术有限公司 | 一种盐酸氨基乙酰丙酸酯的制备工艺 |
| CN102649767A (zh) * | 2011-02-25 | 2012-08-29 | 上海泺安医药技术有限公司 | 一种n-取代氨基乙酰丙酸及其酯制备新工艺 |
| CN102179010B (zh) * | 2011-05-27 | 2013-01-09 | 吉林大学 | 脑胶质瘤光动力直接照射治疗装置 |
| EP2727603B1 (en) * | 2011-07-01 | 2023-09-06 | SBI Pharmaceuticals Co., Ltd. | Photodynamic therapy using photosensitizing agent or 5-aminolevulinic acid |
| US20140276107A1 (en) | 2011-10-14 | 2014-09-18 | Photocure Asa | Photodynamic diagnosis |
| WO2013053904A1 (en) | 2011-10-14 | 2013-04-18 | Photocure Asa | Stent |
| JP2015500717A (ja) | 2011-12-19 | 2015-01-08 | フォトキュア エイエスエイ | 照射装置 |
| WO2013092936A2 (en) | 2011-12-20 | 2013-06-27 | Galderma Research & Development | Use of 5-aminolevulinic acid and esters, in combination with a vitamin d derivative or analog in photochemotherapy, and their uses in treating acne |
| US9488664B2 (en) | 2012-01-25 | 2016-11-08 | Sbi Pharmaceuticals Co., Ltd. | Diagnostic agent for tumor |
| JP5889398B2 (ja) | 2012-04-05 | 2016-03-22 | Ｓｂｉファーマ株式会社 | センチネルリンパ節がん転移識別装置 |
| RU2635563C2 (ru) | 2012-08-03 | 2017-11-14 | ФотоКьюэр АСА | Соединения |
| US20140067024A1 (en) | 2012-08-30 | 2014-03-06 | Photocure Asa | Dual panel photodynamic therapy lamp |
| GB201221123D0 (en) | 2012-11-23 | 2013-01-09 | Photocure As | Device for photodynamic treatment |
| GB201306369D0 (en) | 2013-04-09 | 2013-05-22 | Photocure As | Irradiation device |
| US10716855B2 (en) | 2013-12-20 | 2020-07-21 | Galderma Research & Development | Pulse photodynamic treatment of photodamaged skin |
| EP3095464A1 (en) | 2015-05-19 | 2016-11-23 | Universite De Geneve | 5-ala derivatives and use thereof |
| GB201522311D0 (en) | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| GB201522309D0 (en) | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| BR112018011965A2 (pt) | 2015-12-17 | 2018-12-04 | Photocure Asa | método de terapia fotodinâmica (pdt) para câncer de bexiga |
| GB201522398D0 (en) | 2015-12-18 | 2016-02-03 | Photocure As | Device for photodynamic therapy |
| CN106187793A (zh) | 2016-01-26 | 2016-12-07 | 赵鸣 | 5‑氨基酮戊酸及其衍生物的盐化合物和应用 |
| ES2981753T3 (es) | 2017-02-06 | 2024-10-10 | 3Skin As | Composición de filtro solar |
| CN110730658B (zh) | 2017-05-31 | 2023-01-24 | 思佰益药业股份有限公司 | 膀胱过度活动的预防剂或治疗剂 |
| CN107976508A (zh) * | 2017-11-27 | 2018-05-01 | 上海百灵医药科技有限公司 | 一种分析盐酸氨酮戊酸含量和纯度的方法 |
| EP3868372A1 (en) | 2020-02-19 | 2021-08-25 | JLP Health GmbH | A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer |
| CN113651708A (zh) * | 2021-08-17 | 2021-11-16 | 湖南复瑞生物医药技术有限责任公司 | 一种5-氨基酮戊酸酯化物的制备及后处理方法 |
| WO2024184417A1 (en) | 2023-03-07 | 2024-09-12 | Photocure Asa | Therapy for bladder cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2411382C3 (de) * | 1974-03-09 | 1979-09-06 | C.H. Boehringer Sohn, 6507 Ingelheim | 2-Tetrahydrofurfuryl-6,7-benzomorphane, Verfahren zur Herstellung und deren Verwendung |
| GB2058077B (en) * | 1979-06-08 | 1983-03-09 | Szelke M | Enkephalin analogues |
| CA1236029A (en) * | 1984-05-14 | 1988-05-03 | Edmund Sandborn | Pharmaceutical solutions comprising dimethyl sulfoxide |
| JPH0745502B2 (ja) * | 1987-11-10 | 1995-05-17 | 株式会社トクヤマ | 新規化合物及びそれを含む組成物 |
| US5079262A (en) * | 1989-07-28 | 1992-01-07 | Queen's University At Kingston | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid |
| US5422093A (en) * | 1989-07-28 | 1995-06-06 | Queen's University | Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof |
| US5234940A (en) * | 1989-07-28 | 1993-08-10 | Queen's University | Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof |
| JP2767318B2 (ja) * | 1990-04-11 | 1998-06-18 | 株式会社コスモ総合研究所 | ５―アミノレブリン酸アルキルエステル又はその塩及びその製造方法並びにこれを有効成分とする除草剤 |
| AU655942B2 (en) * | 1990-10-05 | 1995-01-19 | Queen's University At Kingston | Porphyrin derivatives |
| US5219878A (en) * | 1990-10-05 | 1993-06-15 | Queen's University | Tetrapyrrole hydroxyalkylamide photochemotherapeutic agents |
| GB9318841D0 (en) * | 1993-09-10 | 1993-10-27 | Res Foundation Of The Norwegia | Composition |
-
1996
- 1996-03-08 AU AU49500/96A patent/AU708076B2/en not_active Expired
- 1996-03-08 DE DE1996613365 patent/DE122006000051I1/de active Pending
- 1996-03-08 CA CA002215069A patent/CA2215069C/en not_active Expired - Lifetime
- 1996-03-08 ES ES96905940T patent/ES2157424T3/es not_active Expired - Lifetime
- 1996-03-08 EP EP96905940A patent/EP0820432B1/en not_active Expired - Lifetime
- 1996-03-08 WO PCT/GB1996/000553 patent/WO1996028412A1/en active IP Right Grant
- 1996-03-08 AT AT96905940T patent/ATE202076T1/de active
- 1996-03-08 NZ NZ303251A patent/NZ303251A/xx not_active IP Right Cessation
- 1996-03-08 CZ CZ19972848A patent/CZ291132B6/cs not_active IP Right Cessation
- 1996-03-08 DE DE122006000051C patent/DE122006000051I2/de active Active
- 1996-03-08 CN CNB961924799A patent/CN1137087C/zh not_active Expired - Lifetime
- 1996-03-08 KR KR1019970706305A patent/KR100444007B1/ko not_active IP Right Cessation
- 1996-03-08 JP JP52736896A patent/JP3955093B2/ja not_active Expired - Lifetime
- 1996-03-08 US US08/913,257 patent/US6034267A/en not_active Expired - Lifetime
- 1996-03-08 PT PT96905940T patent/PT820432E/pt unknown
- 1996-03-08 DE DE69613365T patent/DE69613365T2/de not_active Expired - Lifetime
- 1996-03-08 HU HU9800460A patent/HU225148B1/hu active Protection Beyond IP Right Term
-
1997
- 1997-09-09 NO NO19974163A patent/NO318379B1/no not_active IP Right Cessation
-
2002
- 2002-09-13 LU LU90956C patent/LU90956I2/fr unknown
-
2005
- 2005-02-17 NL NL300176C patent/NL300176I2/nl unknown
- 2005-09-13 NO NO2005019C patent/NO2005019I2/no unknown
- 2005-10-05 FR FR05C0042C patent/FR05C0042I2/fr active Active
- 2005-10-07 NL NL300207C patent/NL300207I1/nl unknown
- 2005-11-07 NO NO2005024C patent/NO2005024I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO318379B1 (no) | Ester av 5-aminolevulinsyre som fotosensibiliseringsmiddel i fotokjemoterapi, anvendelse derav, samt farmasoytisk blanding, produkt, utstyrsett og fremgangsmate for in vitro-diagnostisering. | |
| US7335684B2 (en) | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | |
| US7850008B2 (en) | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | |
| US7217736B2 (en) | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | |
| EP1727786B1 (en) | Acid addition salts of 5-aminolevulinic acid or its derivatives | |
| AU2002227495A1 (en) | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | |
| KR20000070040A (ko) | 광화학적 치료 조성물 | |
| US7287646B2 (en) | Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy | |
| RU2191010C2 (ru) | Сложные эфиры 5-аминолевулиновой кислоты в качестве фотосенсибилизаторов в фотохимиотерапии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: METVIX KREM 160 MG/G; NAT. REG. NO/DATE: 01/8209SE/H/266/01 20020117; FIRST REG. NO/DATE: SE , 16338 20010615 Spc suppl protection certif: 2005019 Filing date: 20050913 |
|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: HEXVIX 85 MG PULVER OG VAESKE; NAT. REG. NO/DATE: 04/308/SE/H/0478/001 20050525; FIRST REG. NO/DATE: SE , 19227 20040917 Spc suppl protection certif: 2005024 Filing date: 20051107 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: METVIX KREM 160 MG/G; NAT. REG. NO/DATE: 01/8209SE/H/266/01 20020117; FIRST REG. NO/DATE: SE , 16338 20010615 Spc suppl protection certif: 2005019 Filing date: 20050913 Extension date: 20160615 Free format text: PRODUCT NAME: HEXVIX 85 MG PULVER OG VAESKE; NAT. REG. NO/DATE: 04/308/SE/H/0478/001 20050525; FIRST REG. NO/DATE: SE , 19227 20040917 Spc suppl protection certif: 2005024 Filing date: 20051107 Extension date: 20190917 |
|
| MK1K | Patent expired | ||
| SPCX | Expiry of an spc |
Free format text: PRODUCT NAME: METYLAMINOLEVULINAT, EVENTUELT I FORM AV ET SALT, FORTRINNSVIS METYLAMINOLEVULINAT-HYDROKLORID Spc suppl protection certif: 2005019 |
|
| SPCX | Expiry of an spc |
Free format text: PRODUCT NAME: HEKSYLAMINOLEVULINAT, EVENTUELT I FORM AV ET SALT, FORTRINNSVIS HEKSYLAMINOLEVULINATHYDROKLORID Spc suppl protection certif: 2005024 Effective date: 20190917 |